163 related articles for article (PubMed ID: 12010361)
21. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
22. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
[TBL] [Abstract][Full Text] [Related]
23. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
[TBL] [Abstract][Full Text] [Related]
25. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F
Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814
[TBL] [Abstract][Full Text] [Related]
26. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
27. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
28. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.
Loveday C
J Acquir Immune Defic Syndr; 2001 Mar; 26 Suppl 1():S10-24. PubMed ID: 11264998
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I
J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050
[TBL] [Abstract][Full Text] [Related]
30. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
Miller MD; Haddad M; Su C; Gibbs C; McColl DJ; Guyer B
Antivir Ther; 2012; 17(6):993-9. PubMed ID: 22837442
[TBL] [Abstract][Full Text] [Related]
31. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
32. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
33. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
Quan Y; Gu Z; Li X; Liang C; Parniak MA; Wainberg MA
J Mol Biol; 1998 Mar; 277(2):237-47. PubMed ID: 9514745
[TBL] [Abstract][Full Text] [Related]
34. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
Lanier ER; Givens N; Stone C; Griffin P; Gibb D; Walker S; Tisdale M; Irlbeck D; Underwood M; St Clair M; Ait-Khaled M
HIV Med; 2004 Nov; 5(6):394-9. PubMed ID: 15544690
[TBL] [Abstract][Full Text] [Related]
35. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
Descamps D; Joly V; Flandre P; Peytavin G; Meiffrédy V; Delarue S; Lastère S; Aboulker JP; Yeni P; Brun-Vézinet F
J Clin Virol; 2005 Jun; 33(2):99-103. PubMed ID: 15911424
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase.
Feng JY; Anderson KS
Biochemistry; 1999 Jul; 38(29):9440-8. PubMed ID: 10413520
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
38. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.
Götte M; Arion D; Parniak MA; Wainberg MA
J Virol; 2000 Apr; 74(8):3579-85. PubMed ID: 10729133
[TBL] [Abstract][Full Text] [Related]
39. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.
Hertogs K; Bloor S; De Vroey V; van Den Eynde C; Dehertogh P; van Cauwenberge A; Stürmer M; Alcorn T; Wegner S; van Houtte M; Miller V; Larder BA
Antimicrob Agents Chemother; 2000 Mar; 44(3):568-73. PubMed ID: 10681319
[TBL] [Abstract][Full Text] [Related]
40. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
Andreatta KN; Goodman DD; Miller MD; White KL
Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
